Entity

Time filter

Source Type


Machado D.E.,Centro Universitario Estadual da Zona Oeste | Perini J.A.,Centro Universitario Estadual da Zona Oeste | Orlando M.M.C.,University Hospital Pedro Ernesto | Santos-Oliveira R.,Laboratory of Nanoradiopharmaceuticals
BioMed Research International | Year: 2015

The off-label use of bevacizumab labeled with 99mTc as a new radiopharmaceutical for imaging of endometriosis is a promising noninvasive, new clinical procedure. The bevacizumab in monoclonal antibodies targeted at vascular endothelial growth factor (VEGF) is superexpressed in cases of endometriosis. In this study we evaluate the imaging of endometriosis lesion in rats (induced to endometriosis) using bevacizumab-99mTc. The results showed that bevacizumab-99mTc imaged the lesion and support his use for Nuclear Medicine applied to gynecology. Also the results appointed that this radiopharmaceutical has a hepatobiliary excretion. It is important to notice that the dose used was almost 0,01% of the usual dose for the bevacizumab. Copyright © 2015 Daniel Escorsim Machado et al. Source


De Carvalho Patricio B.F.,Laboratory of Nanoradiopharmaceuticals | Lima-Ribeiro M.H.M.,University of Pernambuco | Correia M.T.D.S.,Federal University of Pernambuco | Carneiro-Leao A.M.D.A.,Federal University of Pernambuco | And 4 more authors.
International Journal of Peptides | Year: 2011

The cramoll 1,4 is a well-studied lectin. However, few studies about its biodistribution have been done before. In this study, we radiolabeled the cramol 1,4 with Tc-99m and analyzed the biodistribution. The results showed that the cramol has an abnormal uptake by the bowel with reflections on its clearance mechanism. Copyright © 2011 Beatriz Ferreira de Carvalho Patricio et al. Source


Coelho B.F.,Laboratory of Nanoradiopharmaceuticals | Coelho B.F.,University of Sao Paulo | Albernaz M.S.,Laboratory of Nanoradiopharmaceuticals | Iscaife A.,University of Sao Paulo | And 5 more authors.
Current Cancer Drug Targets | Year: 2015

Drug delivery systems are under intense investigation all around the world, especially in oncology research. Indeed, in some cases, like bone metastasis, nanodrugs may represent the last and best choice for both treatment and imaging of early cancer foci. Nuclear medicine has been using MDP labelled with 99mTc as radiopharmaceuticals for many years; however, their use as nanoradiopharmaceuticals is very innovative and creates a new way to establish radiopharmacy in this new scenario offered by nanotechnology. In this study we developed and tested nano-MDP-labelled with 99mTc in rats induced with bone cancer metastasis and the results showed that it may work in patients. However, some further experiments are required in order to initiate protocols in humans. © 2015 Bentham Science Publishers. Source


Ligiero T.B.,Laboratory of Nanoradiopharmaceuticals | De Souza Albernaz M.,Federal University of Rio de Janeiro | De Carvalho S.M.,Laboratory of Nanoradiopharmaceuticals | De Oliveira S.M.V.,Radiation Protection Institute | Santos-Oliveira R.,Laboratory of Nanoradiopharmaceuticals
Current Radiopharmaceuticals | Year: 2013

In this study was carried on a systematic review of the data was carried out in the topic of monoclonal antibodies in the last 40 years. All the data collected and summarized revealed that this new class of medicine may bring great advance in the field of radiopharmacy, oncology and imaging. © 2013 Bentham Science Publishers. Source


Albernaz M.S.,Laboratory of Nanoradiopharmaceuticals | Patricio B.F.C.,Laboratory of Nanoradiopharmaceuticals | Weissmuller G.,Federal University of Rio de Janeiro | Reynaud F.,University of Bergen | And 3 more authors.
Current Radiopharmaceuticals | Year: 2012

Nanotechnology has been the last frontier in the diagnoses and treatment of many diseases, especially in oncology. The use of nanoparticles of radiopharmaceuticals may represent the future of Nuclear Medicine. In this study we developed, characterized and tested polymeric nanoparticles of FMISO (fluoromisonidazole) in a dynamic study of biodistribution. The results of the development as characterization showed that nanoparticles were well obtained with a size range of 300- 500nm and a spherical shape. © 2012 Bentham Science Publishers. Source

Discover hidden collaborations